Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.
We conducted a double-blind, vehicle-controlled, dose escalation safety and immunogenicity trial of a candidate herpes simplex virus type 2 (HSV-2) surface glycoprotein D2 (gD2) DNA vaccine administered by use of a needle-free device. Sixty-two healthy adults were randomized using a 4:1 vaccine-to-placebo ratio. Half of the participants were HSV-1 seronegative, and all were HSV-2 seronegative. Vaccine doses included 100 microg, 300 microg, 1,000 microg or 3,000 microg of a plasmid expressing the gD2 protein. Subjects received vaccine at 0, 4, 8, and 24 weeks. Some subjects received an additional 1,000-microg boost at 52 weeks. We found that the vaccine was safe and well tolerated, with most adverse events being local site reactions. No dose-limiting toxicities were observed. gD2-specific cytotoxic T-lymphocyte and lymphoproliferation responses were detected 2 weeks after the third vaccine injection in one of four HSV-1-seronegative, HSV-2-seronegative participants who received 3,000 microg of vaccine. A DNA-based vaccination strategy against HSV-2 appears to be safe and may generate a vaccine-specific cellular immune response, but high vaccine doses are likely needed to elicit an immune response in most vaccinees.
Cattamanchi
Ashok
A
Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Posavad
Christine M
CM
Wald
Anna
A
Baine
Yaela
Y
Moses
Jennifer
J
Higgins
Terry J
TJ
Ginsberg
Richard
R
Ciccarelli
Richard
R
Corey
Lawrence
L
Koelle
David M
DM
D000328:Adult; D049109:Cell Proliferation; D003601:Cytotoxicity Tests, Immunologic; D004311:Double-Blind Method; D005260:Female; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D018258:Herpesvirus 2, Human / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007267:Injections / Q000379:methods; D008297:Male; D008875:Middle Aged; D010919:Placebos / Q000008:administration & dosage; D010957:Plasmids; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination / Q000379:methods; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology
D022301:Herpes Simplex Virus Vaccines; D010919:Placebos; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2
J Clin Microbiol. 1988 Apr;26(4):662-7
2835389
Mol Cell Biol Hum Dis Ser. 1995;5:368-87
9532575
J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):435-45
15021308
Curr Top Microbiol Immunol. 1998;226:79-89
9479837
N Engl J Med. 2007 Feb 22;356(8):854-6
17314346
J Virol. 2000 Dec;74(23):11422-5
11070045
Vaccine. 2003 Mar 7;21(11-12):1239-45
12559804
J Immunol. 2003 Apr 15;170(8):4380-8
12682275
JAMA. 1999 Jul 28;282(4):331-40
10432030
J Clin Invest. 1993 Mar;91(3):961-8
8383706
Vaccine. 1998 Nov;16(19):1822-7
9795387
J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):601-5
17325604
Clin Vaccine Immunol. 2006 Nov;13(11):1267-77
16988008
Vaccine. 2005 Sep 23;23(40):4867-78
15985318
J Med Virol. 1985 Oct;17(2):153-66
2997384
J Virol. 1994 May;68(5):2803-10
7512152
Vaccine. 1999 Apr 9;17(15-16):1964-9
10217595
Rev Med Virol. 2005 Sep-Oct;15(5):303-25
15906276
Rev Gastroenterol Peru. 2003 Oct-Dec;23(4):259-64
14716420
J Virol. 2006 Jun;80(11):5509-15
16699031
Vaccine. 1999 Jun 4;17(20-21):2517-27
10418898
J Clin Invest. 1998 Apr 1;101(7):1500-8
9525993
J Immunol. 1998 Jun 15;160(12):6093-100
9637526
Virology. 1997 Mar 3;229(1):259-68
9123869
J Virol. 1992 Mar;66(3):1622-34
1310769
Clin Microbiol Rev. 2004 Jan;17(1):1-13
14726453
N Engl J Med. 2002 Nov 21;347(21):1652-61
12444179
J Infect Dis. 2006 Dec 15;194(12):1650-60
17109336
Vaccine. 1993;11(4):407-14
8385842
Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10289-94
9294203
Vaccine. 2007 Nov 7;25(45):7737-42
17920731
AIDS Res Hum Retroviruses. 2004 Aug;20(8):860-70
15320990